Bifidobacterium animalis subsp. lactis A12 prevents obesity-associated dyslipidemia by modulating gut microbiota-derived short-chain fatty acid production and energy metabolism in high-fat diet-fed mice

Background : Bifidobacterium lactis A12 ( B. lactis A12) has been shown to have the potential to prevent obesity. However, the mechanisms by which it affects the control of energy metabolism have not been fully elucidated. Objective : The present work aimed to clarify the mechanisms by that B. lactis A12 has an effect on the management of energy metabolism. Design : Three- to five-week-old male C57BL/6J mice were randomly divided into five groups, 15 mice for each group. Low-fat diet (LFD) group and high-fat diet (HFD) group were fed with phosphate-buffered saline (PBS) on a daily basis. Cell-free supernatant (CFS), A12, and B. lactis BB12 (BB12) groups were fed with daily probiotics for 10 weeks (1 × 10 9 CFU of every strain). Results : The results showed that A12 effectively alleviated relieved weight gain and dyslipidemia, inhibited liver adipose accumulation, and improved leptin resistance in HFD-fed mice ( p < 0.05). The anti-obesity effects of B. lactis A12 were closely related to the assembly of short-chain fatty acids (SCFAs), SCFA-down-stream receptors, and glucagon-like peptide-1 (GLP-1) secretion. Additionally, high-throughput sequencing of the 16S rRNA showed that B. lactis A12 supplementation reversed HFD-induced gut microbiota dysbiosis, which was possible related to the augmented abundance of SCFA-producing bacterium and a minimized ratio of Bacteroidetes to Firmicutes in mice. Conclusions : B. lactis A12 prevents obesity in some pathways, including the downregulation of sterol regulatory element binding protein-1 mRNA levels in the liver, modulation of the structure of gut microbiota in a gut microbiota-dependent manner, and the upregulation of the SCFA-producing bacteria-related G protein-coupled receptor 43 pathway.

O besity has become a worldwide health problem, and as a result, its prevalence has increased rapidly within the last decades (1). Obesity, often characterized by the consumption of a high-calorie/fat diet and lacking of physical activity and referred to as a sort of clinical metabolic syndrome, appears because it cannot fully promote the utilization of fatty acids and the imbalance of lipid metabolism when intake surpasses energy consumption (2). At present, more and more research is devoted to find the effective treatment methods to decline the obesity rate. Some synthetic drugs used to treat obesity cause side effects and secondary failure (3,4). Moreover, prevention is the best treatment option for any disease. Therefore, it is important to seek more natural and safer materials to prevent obesity.
Generally, probiotics colonize the intestinal tract and are beneficial to the health of the host. The gut origin of chronic diseases indicates that metabolic diseases are closely associated with gut microbiota (5,6). Recent studies have highlighted that probiotics may exert their beneficial effects through the gut microbiota (7,8). However, numerous studies have shown that probiotic mixtures can treat metabolic diseases, and research on a single strain has mainly focused on Lactobacillus (9)(10)(11).
Bifidobacterium is one of the major microbiota in the human intestinal tract, and some of its members are the most commonly used human probiotics (12,13). However, the prospects of Bifidobacterium application in metabolic diseases have not been extensively explored, and the molecular mechanisms have not been fully elucidated, but it may be related to the regulation of gut microbiota (14).
Our previous in vivo studies have shown that B. lactis A12, a novel probiotic strain isolated from breast-fed infant faces, had a positive influence on the management of diabetes-related parameters, like blood glucose (15) and eased constipation (16), and some studies have suggested that probiotics appear to normalize gut dysbiosis in mice (10). We hypothesized that gut microbiota may play a vital role in the improvement of obesity by B. lactis A12. Thus, the potential mechanisms were clarified by this study. Our results shown that two separate regulatory pathways connecting intestinal flora and energy metabolism may be associated with the anti-obesity actions of B. lactis A12.

Materials and methods
Bacteria strain and culture condition Bifidobacterium animalis subsp. lactis A12 strain (CGMCC No. 17308) was originally isolated from the fecal matter of a 1-month-old infant (vaginal delivery and breastfed) and identified by sequencing amplified 16S rDNA regions as described previously (15).
B. lactis A12 was cultured on improved De Man-Rogosa-Sharpe (MRS) medium (1L medium contained 20 g maltose, 10 g beef extract, 5 g soy peptone, 5 g malt extract, 5 g CH 3 COONa·3H 2 O, 2 g C 6 H 5 O 7 (NH 4 ) 3 , 2 g K 2 HP0 4 ·3H 2 O, 1 ml Tween 80, 0.58 g MgSO 4 ·7H 2 O, 0.5 g l-cysteine hydrochloride, and 0.25 g MnSO 4 ·H 2 O), and pH was altered to 6.5, 37°C anaerobic culture for 12 h. The bacterial suspensions were centrifuged at 8,000 ×g (10 min, 4°C), washed three times with phosphatebuffered saline (phosphate-buffered saline (PBS), pH 7.4, Gibco, Life Technologies, Ghent, Belgium), and adjusted to a live bacterial concentration of 10 9 CFU/mL. The pH of B. lactis A12 cell-free supernatant (CFS) was altered to 6.5 and filtered through a 0.22 μm pore-size sterile filter (Millipore, Burlington, MA, USA). B. lactis BB12 was used as a reference strain because it has been widely used in commercial functional foods and has the potential to prevent obesity. To access the supplementary material, please visit the article landing page n = 15); BB12 group (HFD and live B. lactis BB12 cells, n = 15). All probiotics were administered daily for 10 weeks (1 × 10 9 CFU of each strain). In addition, we measured the weight of mice every week.

Histological evaluation
The liver tissues of mice were excised and treated as previously described (17). We quickly removed liver tissues, rinsed it with saline, and then fixed a tissue mass of approximately 2.0 cm×2.0 cm×0.3 cm size with 4% formaldehyde (Nanjing Jiancheng, Nanjing, China). After dehydration, paraffin embedding, and sectioning, liver tissue sections were stained with hematoxylin and eosin (H&E) staining. The histopathological changes of each tissue were observed with camera accessories under a high-resolution microscope (Nikon Eclipse Ti-SR, Japan).

Analysis of gene expression
Real-time polymerase chain reaction (RT-PCR) was used to analyze the relative transcript levels of β-actin, sterol regulatory element binding protein-1 (SREBP-1), peroxisome proliferator-activated receptors (PPAR-γ), G-protein coupled receptors (GPR43), glucagon (GCG), and prohormone convertase 3 (PC3). Following the manufacturer's protocol, the TRIzol reagent (Ambion, Austin, TX, USA) was used to extract total RNA in colon and liver tissues. We used the PrimeScript™ II 1st Strand cDNA Synthesis Kit (TaKaRa, Kyoto, Japan) to obtain complementary DNA (cDNA) through reverse transcription. The primers used are listed in Table 1. PCR reaction conditions referred to our previous studies (15). Using the 2 −ΔΔCt method, mRNA abundance was calculated (reference gene:β-actin) and expressed as a percentage of the control group induction (calibrator) (18).

Short-chain fatty acid (SCFA) concentrations quantified using gas chromatography (GC)
Fecal samples (0.2g) of the colon were collected immediately after the animals were dissected into a covered sterile centrifuge tube and then stored at -80°C until use. The SCFAs in feces were analyzed by GC, including acetate, propionate, and butyrate. According to the method of Goossens et al., we slightly modified it to analyze the SCFA concentration (19). We added 10 mmol/L HCl (1 mL) containing heptanoic acid (internal standard, Sigma Aldrich, Merck, Germany) to 1 mL of diluted fecal samples to form free fatty acids. SCFAs were extracted using 1 mL of diethyl ether, then transferred to a tube of 1.5 mL containing 0.3 g glass beads (Φ = 100 μm), and homogenized the mixture twice in a bead-beater chamber (Thermo Scientific, MA, USA) for 30 s each time. The solution was centrifuged (5,000 ×g for 2 min, at 4°C) and then filtered through a 0.22 μm sterile filter (Millipore, Burlington, MA, USA). One microliter of the supernatant was injected for measurement. SCFA concentration was measured as the number of millimoles per gram of feces after dilution correction.

DNA extraction and high throughput sequencing
Fecal samples collected using a sterile centrifuge tube with a lid were stored at -80°C until assay. We extracted DNA using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany). Each 20μL PCR mixtures was as follows: 5 × TransStart FastPfu buffer 4 μL, 2.5 mM dNTPs 2 μL, forward primer (5 μM) 0. 8  Biosciences, Union City, USA) was used for purifying, following the manufacturer's instructions, and the Quan-tiFluor™-ST Kit (Promega, USA) was used to quantify. The raw reads were stored in the NCBI Sequence Read Archive (SRA) database (Accession Number: SRP213006). In brief, raw FASTQ files were demultiplexed and quality-filtered using QIIME (version 1.17), and operational units (OTUs) were clustered with a 97% similarity cutoff using UPARSE (version 7.1, http:// drive5.com/uparse/); chimeric sequences were identified and removed using UCHIME. The taxonomy of each 16S rRNA gene sequence was analyzed using the RDP Classifier (http://rdp.cme.msu.edu/) against the Silva (SSU115) 16S rRNA database (Release 128 http:// www.arb-silva.de) using a confidence threshold of 70% (20). So, we explored the changes of bacterial community structure in each experimental group from the level of phylum and genus. The linear discriminant analysis effect size (LEfSe) and the PICRUSt software were used to analyze 16S rRNA data.

Statistical analysis
Data are indicated as the mean ± standard deviation (SD). The SPSS 16.0 software was used to analyze data by one-way analysis of variance (ANOVA). GraphPad Prism software was used for graphing. The Networkx software was applied to the Spearman correlation network between bacteria at the genus level. P value < 0.05 was indicated statistically significant. Except for animal experiments, three parallel tests were carried out in the assays.

Effects of B. lactis A12 on physiologic and metabolic parameters
Continued intake of HFD for 10 weeks caused the development of obesity-associated dyslipidemia, which was mainly manifested in increased body weight gain, serum TG, T-CHO, and leptin levels, compared with the LFD group. Body weights of all groups increased after 10 weeks (Table 2). During the experiment, although there was no clear difference in body weights among LFD, CFS, A12, and BB12 groups, the HFD group was more than all these groups. It suggested that HFD-induced body weight and weight gain are prevented in mice treated with CFS, A12, and BB12. The CFS (2.26 g), A12 (2.65 g), and BB12 groups (2.66 g) displayed lower food intake than the HFD (3.32 g) group. In contrast, no significant difference was regarded between the LFD (3.04 g) group and the HFD group. Consistently, due to the different calories between the diets, the LFD (11.72 kcal), CFS (11.85 kcal), A12 (13.90 kcal), and BB12 groups (13.95 kcal) displayed less energy intake compared with the HFD group (17.39 kcal) ( Table 2).
The liver is an important organ that participates in glucose and lipid metabolism. Epididymal fat, which is a white adipose tissue, represents the excess energy accumulated. Therefore, we examined the weight of liver and epididymal fat mass. Compared with the HFD group, the liver weight and epididymal fat mass in the LFD, CFS, A12, and BB12 groups were significantly decreased (p < 0.05) ( Table 2). Changes in lipid and hormone levels were also investigated. Our results suggested that serum levels of T-CHO, TG, and leptin in the HFD group had a significant increase compared with the LFD group, while adiponectin levels showed the opposite trend. The serum concentration of T-CHO was decreased in the CFS (3.44 mmol/L) and A12 (3.30 mmol/L) groups compared with the HFD group, and there was no significant difference between the BB12 (4.89 mmol/L) group and the HFD (7.33 mmol/L) group. Likewise, the CFS (0.48 mmol/L) group decreased in TG levels compared with the HFD group. However, there was no significant difference between the A12 (0.62 mmol/L) and BB12 (0.77 mmol/L) groups compared with the HFD (0.92 mmol/L) group. Additionally, leptin levels were decreased in the CFS (2.65 ng/mL) and A12 (2.38 ng/mL) groups compared with the HFD group (4.04 ng/mL). Furthermore, A12 (8.13 mg/L) and BB12 (7.41 mg/L) groups exhibited increased serum adiponectin levels compared with the HFD group (Table 2).
In short, these results indicated that continuous intake of B. lactis A12 CFS, live B. lactis A12 cells, or live B. lactis BB12 cells can reduce metabolic disorders in obese and leptin resistant mice.

Effects of B. lactis A12 treatment on histology in liver tissue
The liver has a central role in lipid metabolism. Adipose in the liver originates from food and peripheral tissues. Compared with the LFD histological section, the section of liver in the HFD group showed a large number of fat vesicles, which characterized hepatic steatosis (red arrow).
However, the CFS, A12, and BB12 groups did not exhibit fat accumulation in the liver parenchyma (Fig. 1).

mRNA expression of genes involved in adipogenesis in liver tissue
Adipogenesis is a process in which preadipocytes differentiate into adipocytes. Several transcription factors and binding proteins, including the PPAR and SERBP families, are expressed sequentially and cooperatively during adipocyte differentiation. PPAR-γ is a key regulatory factor in adipogenesis and influences adipose accumulation. SERBP-1 regulates adipose synthesis (1).
Compared with the HFD group, all groups exhibited a decreased PPAR-γ mRNA expression in liver tissue (p > 0.05) (Fig. 2). SERBP-1 mRNA levels in liver tissue decreased in the CFS, A12, and BB12 groups compared with the HFD group, but only the expression level of SERBP-1 mRNA in the CFS group decreased significantly (Fig. 2B). Our findings showed that B. lactis A12 reduced the gene expression of PPAR-γ and SERBP-1, which led to a reduction in fat deposition in the liver.

B. lactis A12 improved SCFAs-producing capacity and enhanced mRNA levels of GPR43
It has been suggested that SCFAs are produced by insoluble carbohydrates, which are fermented in the colon by probiotics. SCFAs play a pivotal role in regulating the balance of the intestinal microecological environment and host metabolism (21,22). To investigate the content of SCFAs regulated by B. lactis A12, we quantified SCFA concentrations  in faces by GC. The concentrations of acetic acid and propionic acid were higher in the CFS and A12 groups than in the HFD group, and there was no significant difference among the LFD, BB12, and HFD groups. Butyric acid levels were increased in the A12 (0.269 mmol/g) and BB12 (0.270 mmol/g) groups compared with the HFD group, and there was no significant difference among the LFD (0.197 mmol/g), CFS (0.233 mmol/g), and HFD (0.196 mmol/g) groups (Fig. 3A, B, and C). SCFAs confer some of their biological effects via G protein-coupled receptors (GPRs), known as GPR43, which has beneficial roles in energy and glucose homeostasis (23,24). Consequently, we further investigated mRNA expression of GPR43 in colon tissue. All groups significantly increased the mRNA expression of GPR43 compared with the HFD group. Together, these results indicated that the CFS, A12, and BB12 groups could upregulate GPR43 mRNA levels and promote the production of SCFAs (Fig. 3D).

Secretion and expression of GLP-1 in vivo
Probiotics usually colonize and play vital roles in the intestinal tract, and some endocrine hormones in the intestinal tract may be the key targets underlying these beneficial functions. GLP-1 is synthesized and secreted by enteroendocrine L-cells in the whole small and large intestine, and proglucagon is processed after translation by PC3 (25,26). GLP-1 can enhance glucose and lipid homeostasis by reducing food intake and stimulating insulin secretion. Butyrate has been suggested to stimulate the secretion of GLP-1 to exhibit metabolic effects (9). Consequently, the secretion of GLP-1 and the expression of PC3 and GCG genes in colonic tissue were further evaluated.
Compared with the HFD group (0.020 pmmol/L), serum GLP-1 levels in the CFS (0.040 pmmol/L), A12 (0.037 pmmol/L), and BB12 (0.062 pmmol/L) groups were significantly increased (Fig. 4). GCG mRNA levels were significantly increased in all tested groups compared with the HFD group, and the abundance of the PC3 gene was noticeably higher in the A12 and BB12 groups than in the HFD group, but there was no significant difference in PC3 mRNA expression among the CFS, LFD, and HFD groups (Fig. 4B, C). These results indicated that the CFS of B. lactis A12, live B. lactis A12, and B. lactis BB12 cells could increase the expression and secretion of GLP-1.

Effects of B. lactis A12 treatment on gut microbiota
High-throughput sequencing was performed on fecal samples to analyze the effect of B. lactis A12 on the composition of gut microbiota. A total of 2,066,662 high-quality sequences of the V3-V4 region of the 16S rRNA were collected from 20 fecal samples (four groups and five samples per group), and the average sequence length was 418 bp. After removing the low-quality reads, 1,033,331 OTUs at a 97% similarity level were reserved.
Firmicutes and Bacteroidetes were the two major bacterial phyla in all groups (Fig. 5). Compared with the LFD group, a low ratio of Firmicutes to Bacteroidetes was observed in the HFD group. Meanwhile, compared with the HFD (31.15%) group, the CFS (35.46%) and A12 (38.56%) groups increased the relative abundance of Bacteroidetes. A heatmap of Spearman's correlation analysis was performed at the genus level (Fig. 5B), and according to the clustering tree, compared with the HFD group, a similar community composition was shown among the CFS, A12, and LFD groups. In addition, Romboutsia was the dominant genus in the LFD group. Muribaculaceae was dominant in the CFS and A12 groups, and Bacteroides was the major genus in the HFD group.
The LEfSe method was used to analyze the crucial species that changed significantly after all treatments, and the threshold of logarithmic LDA score of 2 was used to distinguish features. According to the size of the LDA score (Fig. 6B)  Helicobacter, Gordonibacter, Bacteroides_uniformis, Bit-tarella_massiliensis, Erysipelatoclostridium, Enterorhabdus, Ruminococcaceae, and Eggerthellaceae significantly increased the gut microbiota of the HFD group. The dominant bacteria in the LFD group were Lactobacillus, Firmicutes, Bifidobacterium, Barnesiella, ASF356, and Rhodospirillales. The CFS group was characterized by Coriobacteriaceae_UCG_002, Dubosiella, Candida-tus_Saccharimonas, Marvinbryantia, Arcobacter, Molli-cutes_RF39, and Coprococcus_3.

Predicted metabolic profile of the fecal microbiome after B. lactis A12 supplementation
In view of the above structural changes, the 16S rRNA data were further analyzed using PICRUSt to predict the metabolism of fecal microbiota in all groups. The Kyoto Encyclopedia of Genes and Genomes database (KEGG, http://www.genome.jp/kegg/) was used for determining whether B. lactis A12 caused obvious changes in the functional pathways of the gut microbiota in mice.
The B. lactis A12 could regulate metabolism, genetic information processing, and environmental information processing-related pathways (Fig. 7). The metabolic pathways involved in purine and pyrimidine metabolism (nucleotide metabolism), starch and sucrose metabolism (carbohydrate metabolism), glycolysis (carbohydrate metabolism), and amino sugar and nucleotide sugar metabolism (carbohydrate metabolism) were characterized. The genetic information processing pathways involved in ribosome and aminoacyl-tRNA biosynthesis (translation) were characterized. The environment information processing pathway involved in ABC transporters (membrane transport).

Discussion
Few studies have focused on the effects of Bifidobacterium, and the molecular mechanisms have not been fully demonstrated (14). Therefore, the current study aimed to elucidate underlying mechanisms of Bifidobacterium-mediated prevention of obesity. Our previous in vivo studies elucidated that B. lactis A12 plays a beneficial role in the management of metabolism-related parameters, including blood glucose and insulin levels (15). In this study, we observed reduced body weight and less energy intake associated with B. lactis A12 administration; meanwhile, B. lactis A12 prevented obesity-associated dyslipidemia and reduced leptin resistance. Liver lipid accumulation is a marker of obesity induced by HFD, and we found that liver weight was noticeably increased in the HFD group, and B. lactis A12 decreased the weight of liver tissue. A study has shown that HFD-induced fatty liver was intervened by a probiotic mixture, consistent with our results (10). In addition, Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating intestinal microbiota, reducing glucose content, and promoting liver carbohydrate metabolism (27). However, we investigated mRNA expression levels of adipose accumulation-and differentiation-related genes. We observed that B. lactis A12 inhibited liver adipose accumulation by downregulating SERBP-1 mRNA levels, which was our new finding on the improvement of obesity by B. lactis A12.
SCFAs are byproducts of non-digestible dietary components metabolized by gut microbiota and have some potential beneficial functions, including maintaining the dynamic equilibrium for intestinal microecology (28) and regulating energy homeostasis (29), which are all closely related to obesity. Various SCFAs, including acetate, propionate, and butyrate, have differential metabolic effects (30,31). Our results demonstrated that B. lactis A12 promoted the enrichment of acetate, propionate, and butyrate. Similar results concerning the beneficial effects of probiotics have also been observed in other studies (32,33). Some studies showed that the expression of GPR43 stimulated by SCFAs can improve glucose tolerance (11). To verify B. lactis A12 could prevent obesity, mediated by promoting the enrichment of SCFAs, we further investigated the mRNA expression of GPR43 in colon tissue. Compared with the HFD group, all groups significantly increased the mRNA expression of GPR43 (Fig. 3B). Together, these results indicated that B. lactis A12 could prevent obesity by upregulating GPR43 mRNA levels and promoting the production of SCFAs. Furthermore, probiotics colonize and play vital roles in the intestinal tract, and we postulate that the intestinal tract may be a key target through which B. lactis A12 improves obesity-related parameters. Some studies showed that intestinal expression of GPR43 improves glucose tolerance and reduces food intake by promoting the secretion of GLP-1 from L cells (34). Additionally, GLP-1 secretion has been related to the modulation of energy homeostasis in other studies (35). Consequently, we evaluated the secretion of GLP-1 and verified the results with the PC3 and GCG expression in colonic tissue. These findings indicated that B. lactis A12 increased the expression and secretion of GLP-1. Taken together, the protective metabolic effects of B. lactis A12 were mediated by SCFA production and the SCFAs-GPR43-GLP-1 pathway.
Because the origin of several chronic diseases resides in the gut, we can conclude that metabolic diseases are closely associated with gut microbiota. Although probiotics have been used for decades, the relationship between gut microbiota, its manipulation, and metabolic syndrome has only recently been the attention. Various strategies have been suggested to adjust these imbalances of gut microbiota (also known as intestinal dysbiosis) in obesity; however, the underlying mechanisms leading to these benefits are unclear (7,8). Consequently, we assessed the effects of B. lactis A12 on the composition of gut microbiota and gut microbial diversity. More importantly, we investigated the correlation between the dominant bacteria, B. lactis A12, and obesity and predicted the metabolic profile of the fecal microbiome. Some studies have reported that a high Bacteroidetes-to-Firmicutes ratio is related to enhanced energy harvesting from food, which suggests that these two main phyla are essential for regulating obesity (36)(37)(38)(39). Consistently, our high-throughput sequencing analysis of gut microbiota demonstrated the prevalence   of Firmicutes increased and Bacteroidetes decreased. The heatmap results (Fig. 5B) at the genus level clarified that the CFS and A12 groups exhibited clear divergences in the community structure of the gut microbiota compared with the HFD group and were similar to the LFD group. To further explore the key species that play a vital role in stimulating the production of SCFAs, the abundance of the top 15 species with significant changes was investigated. Bacteroides_vulgatus, Eggerthellaceae, and Erysipelatoclostridium were the dominant bacteria in the HFD group, similar to previous studies (40). Notably, some beneficial bacteria, including Faecalibaculum (mainly produce butyrate), Anaeroplasma (fermentation of polysaccharides to produce SCFAs), Muribaculaceae (produce succinate, acetate, and propionate), Mollicutes_RFS9 (associated with less weight gain), and Prevotellaceae_UGG_001, were markedly increased in the A12 group (41)(42)(43). In addition, Coriobacteriaceae_UCG_002 (beneficial effects in type 2 diabetes) and Coprococcus_3 (associated with a low body mass index or high microbial richness in both animals and humans) were markedly increased in the CFS group (44,45). Although the effects of Dubosiella, Candidatus_Saccharimonas, Marvinbryantia, Arcobacter, and Mollicutes_RF39 on lipid and glucose metabolism are not well-documented, these might also be conducive to maintain energy homeostasis of the body. Based on this phenomenon, we concluded that B. lactis A12 may regulate the abundance of SCFA-producing bacteria in the gut, thereby regulating the SCFAs' production. Finally, this study predicted the metabolic profile of the fecal microbiome after the B. lactis A12 consumption. Interestingly, B. lactis A12 could regulate metabolism, genetic, and environmental information processing-related pathways in HFD-fed mice, indicating that B. lactis A12 may regulate the gut microbiota in a variety of ways to prevent HFD-induced obesity. However, because of the complexity of the gut microbiota, the precise regulatory mechanism of B. lactis A12 needs to be further elucidated.

Conclusions
In this study, our findings indicated that B. lactis A12, a novel probiotic strain isolated from breast-fed infant faces, can effectively suppress HFD-induced obesity. Two regulatory pathways may be involved in the anti-obesity actions of Fig. 7. Predicted metabolic profile of the fecal microbiome after the B. lactis A12 supplementation. The 16S rRNA data were further analyzed as indicated by the PICRUSt. Statistical significance difference was assessed using the unpaired two-tailed Student's t-test (p < 0.05) in STAMP.
B. lactic A12. First, B. lactis A12 inhibited liver adipose accumulation through downregulation of SERBP-1 mRNA levels. Second, B. lactis A12 increased the abundance of SCFA-producing bacteria in the gut and, eventually, mediated beneficial effects on the host via the SCFAs-GPR43-GLP-1 pathway. Our findings indicated that B. lactis A12 may be potentially used to prevent obesity and metabolic syndrome. Further studies are needed to clarify the mechanisms of specific metabolic interactions modulated by B. lactis A12 and to determine whether these changes play a critical role in human metabolism.